7JO0 and RKV Related Headlines
Go Back- Rakovina Therapeutics plans $1.5M private placement
- Rakovina Therapeutics Announces $1.5 Million Private Placement
- Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update
- Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
- Rakovina Therapeutics presents preclinical cancer therapy data at AACR
- Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
- Rakovina Therapeutics to present cancer research at AACR meeting
- Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum
- Rakovina Therapeutics receives 30-day extension for private placement
- Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
- Rakovina closes $1 million debenture placement, settles $1.6 million debt
- Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
- Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
- Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
- Rakovina Therapeutics secures up to $1.5M in new financing
- Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
- Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
- Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
- Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
- Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
- Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
- Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
- Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
- Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
- Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
- Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
- Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
- Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
- Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
- Rakovina Therapeutics signs letter of intent for joint venture with NanoPalm
- Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
- Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
- Rakovina Therapeutics Announces Stock Option Grants
- Rakovina Therapeutics Announces Warrant Exercise Incentive Program
- Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
7JO0 and RKV Related Press Releases
Go Back- Rakovina Therapeutics Announces $1.5 Million Private Placement
- Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update
- Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
- Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
- Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum
- Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
- Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
- Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
- Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
- Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
- Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
- Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
- Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
- Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
- Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
- Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
- Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
- Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
- Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
- Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
- Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
- Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
- Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
- Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
- Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
- Rakovina Therapeutics Announces Stock Option Grants
- Rakovina Therapeutics Announces Warrant Exercise Incentive Program
- Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
